| |
|
|
|
|
|
 |
| |
|
µå¸²ÆÄ¸¶Å¬·Î¸£Á·»çÁ¸Á¤ CHLORZOXAZONE DR5 TABS.[Chlorzoxazone]
|
|
ÀϹÝÀǾàǰ | »èÁ¦
|
|
|
| |
 |
¾Ë¸²: |
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
655900550[A35100621]
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/1Á¤(2007.11.15)(ÇöÀç¾à°¡)
\22 ¿ø/1Á¤(2005.04.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
|
| ºü¸¥Á¶È¸ |
|
| Á¦Ç°¼º»ó |
¹ÌȲ»öÀÇ Á¤Á¦ÀÓ [Á¦ÇüÁ¤º¸ È®ÀÎ] |
| Æ÷À塤À¯Åë´ÜÀ§ |
20.100.500.1000Á¤ |
| Æ÷À塤ÄÚµå´ÜÀ§ |
| ¾àǰ±Ô°Ý |
´ÜÀ§ |
Æ÷ÀåÇüÅ |
´ëÇ¥ÄÚµå |
Ç¥ÁØÄÚµå |
ºñ°í |
| 200¹Ð¸®±×·¥ |
100 Á¤ |
º´ |
8806559005501 |
8806559005518 |
|
|
| Çã°¡»çÇ× ¿ø¹®Á¶È¸ |
[Çã°¡»çÇ× ¿ø¹®Á¶È¸]
|
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
(°æ±¸ : Á¤Á¦)
±Ù°ñ°Ý°è Áúȯ¿¡ ¼ö¹ÝÇÏ´Â µ¿Å뼺 ¿¬Ãà : ¿ä¹èÅëÁõ, °æ°ß¿ÏÁõÈıº, °ß°üÀýÁÖÀ§¿°, º¯Çü¼º ôÃßÁõ
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
¿ë¹ý¿ë·®
(°æ±¸ : Á¤Á¦)
¼ºÀÎ : Ŭ·Î¸£Á·»çÁ¸À¸·Î¼ 1ȸ 200-400§· 1ÀÏ 3-4ȸ °æ±¸Åõ¿© ÇÑ´Ù.
¿¬·É, Áõ»ó¿¡ µû¶ó ÀûÀýÈ÷ Áõ°¨ÇÑ´Ù.
|
| ±Ý±â |
1) ÀÌ ¾à¿¡ °ú¹ÎÁõÀÇ º´·ÂÀÌ Àִ ȯÀÚ
2) ÀÌ ¾à¿¡ ³»¼ºÀÌ ¾ø´Â ȯÀÚ
|
| ½ÅÁßÅõ¿© |
1) °£½ÅÀå¾Ö ȯÀÚ
2) ¾à¹°¿¡ ¾Ë·¹¸£±â¹ÝÀÀ ¶Ç´Â ±× º´·ÂÀÌ Àִ ȯÀÚ
|
| ÀÌ»ó¹ÝÀÀ |
1) °ú¹ÎÁõ : ¹ßÁø, °¡·Á¿ò, µÎµå·¯±â µîÀÌ ³ªÅ¸³ª´Â °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇÑ´Ù.
2) Á¤½Å½Å°æ°è : Á¹À½, ¾îÁö·¯¿ò, ºñƲ°Å¸², ±Çۨ, °úÀÚ±Ø µîÀÌ ³ªÅ¸³ª´Â °æ¿ì¿¡´Â °¨·® ¶Ç´Â Åõ¿©ÁßÁö µî ÀûÀýÇÑ Ã³Ä¡¸¦ ÇÑ´Ù.
3) °£Àå : µå¹°°Ô °£±â´É Àå¾Ö°¡ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î °üÂûÀ» ÃæºÐÈ÷ Çϰí ÀÌ»óÀÌ ³ªÅ¸³ª´Â °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇÑ´Ù.
4) ¼Òȱâ°è : ±¸¿ª,±¸Åä, °¡½¿¾²¸²À§Á¤Ã¼°¨À§ºÎºÒÄè°¨, ¼³»ç, º¯ºñ, ½É¿ÍºÎÅë,À§Åë, µå¹°°Ô À§Àå°ü ÃâÇ÷ÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
5) ±âŸ : µå¹°°Ô ¾Ë·¹¸£±â¼º ÇǺιßÁø, Á¡»óÃâÇ÷, ¹Ý»óÃâÇ÷, Ç÷°ü½Å°æ¼º ºÎÁ¾, ¾Æ³ªÇʶô½Ã ¹ÝÀÀÀÌ ³ªÅ¸³¯ ¼ö ÀÖ°í ÀÌ ¾àÀÇ Æä³î°è ´ë»ç¹°¿¡ ÀÇÇÑ ¿äº¯»öÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
|
| »óÈ£ÀÛ¿ë |
´ÙÀ½ ¾à¹°°úÀÇ º´¿ë ¶Ç´Â À½ÁÖ¿¡ ÀÇÇÏ¿© »óÈ£ÀÛ¿ëÀÌ Áõ°µÉ ¼ö ÀÖÀ¸¹Ç·Î º´¿ëÅõ¿©ÇÏÁö¾Ê´Â °ÍÀÌ ¹Ù¶÷Á÷ÇÏÁö¸¸ ºÎµæÀÌÇÏ°Ô º´¿ëÇÏ´Â °æ¿ì¿¡´Â °¨·®ÇÏ´Â µî ½ÅÁßÈ÷ Åõ¿©ÇÑ´Ù. : Æä³ëÄ¡¾ÆÁø°è ¾à¹°(Ŭ·Î¸£ÇÁ·Î¸¶Áø µî), ÁßÃ߽Űæ¾ïÁ¦Á¦(¹Ù¸£ºñÅ»°è ¾à¹° µî), MAOÀúÇØÁ¦
|
| Related FDA Approved Drug |
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| ¼ººÐÄÚµå |
M040614/Ŭ·Î¸£Á·»çÁ¸ 200¹Ð¸®±×·¥ /
|
| ´ëÇ¥ÄÚµå |
8806559005501 |
| BIT ¾àÈ¿ºÐ·ù |
±ÙÀÌ¿ÏÁ¦ (Skeletal Muscle Relaxants)
|
| ATC ÄÚµå |
Chlorzoxazone / M03BB03
[ÄÚµåºÐ·ù»ó¼¼¼³¸í]
[ATCÄÚµå¿¹Ãø]
|
| º¹ÁöºÎºÐ·ùÄÚµå |
122 (°ñ°Ý±ÙÀÌ¿ÏÁ¦ )
|
| ÀǾàǰ ¹ÙÄÚµåÁ¤º¸ |
³»¿ëº¸±â
µå¸²ÆÄ¸¶Å¬·Î¸£Á·»çÁ¸Á¤/ A35100621
Á¦Ç°±Ô°Ý: 200¹Ð¸®±×·¥/Á¦Ç°¼ö·®: 100/Á¦Çü: Á¤
Æû¸ñ±âÁØÄÚµå: 197600631 /´ëÇ¥ÄÚµå: 8806559005501/Ç¥ÁØÄÚµå: 8806559005518
±¸¹ÙÄÚµå: -/ºñ°í:-
|
ÁÖ¼ººÐÄÚµå ºÐ¼® ¹× Áߺ¹Ã³¹æ °ËÅä |
[ÁÖ¼ººÐÄÚµå ºÐ¼® ¹× Áߺ¹Ã³¹æ °ËÅä]
|
| Drugs By Indication |
[Àüüº¸±â]
|
| Drugs By Classification |
[Àüüº¸±â]
|
|
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Cµî±Þ
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
| Pharmacokinetics |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾à¶óº§ |
| À̹ÌÁö |
º¹¾à¼³¸í |
 |
º¯ºñ°¡ »ý±æ¼ö ÀÖ½À´Ï´Ù. |
|
 |
¾îÁö·¯¿òÀÌ ÀÖÀ»¼ö ÀÖ½À´Ï´Ù. |
|
|
| * |
º¹¾àÀ̹ÌÁö´Â ¸ðµç º¹¾àÁöµµ »çÇ×À» Ç¥½ÃÇѰÍÀº ¾Æ´Ï¸ç, Ãß°¡ÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ°Å³ª ¼öÁ¤µÉ ¼ö ÀÖ½À´Ï´Ù. |
| * |
º¹¾àÀ̹ÌÁöÀÇ Ç¥½Ã¿©ºÎ´Â ½ÇÁ¦ ¾à¹°º¹¿ë½Ã Á߿䵵¿¡ µû¸¥°ÍÀº ¾Æ´Ï¸ç ´Ü¼øÈ÷ Çã°¡Á¤º¸»ó Ű¿öµå¸¦ ±âÁØÀ¸·Î µî·ÏµÇ¾ú½À´Ï´Ù. |
| * |
±ÍÇϰ¡ º¹¾àÀ̹ÌÁö Á¤º¸¸¦ ½Å·ÚÇÔÀº ÀüÀûÀ¸·Î ±ÍÇÏÀÇ Ã¥ÀÓÀÔ´Ï´Ù. µå·°ÀÎÆ÷´Â ÀÌ¿¡ ´ëÇÑ ¾î¶°ÇÑ º¸Áõµµ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| Mechanism of Action |
Chlorzoxazone¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Chlorzoxazone inhibits degranulation of mast cells, subsequently preventing the release of histamine and slow-reacting substance of anaphylaxis (SRS-A), mediators of type I allergic reactions. Chlorzoxazone also may reduce the release of inflammatory leukotrienes. Chlorzoxazone may act by inhibiting calcium influx.
|
| Pharmacology |
Chlorzoxazone¿¡ ´ëÇÑ Pharmacology Á¤º¸ Chlorzoxazone, a synthetic compound, inhibits antigen-induced bronchospasms and, hence, is used to treat asthma and allergic rhinitis. Chlorzoxazone is used as an ophthalmic solution to treat conjunctivitis and is taken orally to treat systemic mastocytosis and ulcerative colitis. Chlorzoxazone is also a centrally-acting agent for painful musculoskeletal conditions. Data available from animal experiments as well as human study indicate that chlorzoxazone acts primarily at the level of the spinal cord and subcortical areas of the brain where it inhibits multisynaptic reflex a.c. involved in producing and maintaining skeletal muscle spasm of varied etiology. The clinical result is a reduction of the skeletal muscle spasm with relief of pain and increased mobility of the involved muscles.
|
| Metabolism |
Chlorzoxazone¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Cytochrome P450 2E1 (CYP2E1)Cytochrome P450 2C19 (CYP2C19)Cytochrome P450 1A2 (CYP1A2)Cytochrome P450 2A6 (CYP2A6)Cytochrome P450 1A1 (CYP1A1)Cytochrome P450 2D6 (CYP2D6)
|
| Protein Binding |
Chlorzoxazone¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ 13-18%
|
| Half-life |
Chlorzoxazone¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ Not Available
|
| Absorption |
Chlorzoxazone¿¡ ´ëÇÑ Absorption Á¤º¸ Not Available
|
| Pharmacokinetics |
ChlorzoxazoneÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- ÀÛ¿ë¹ßÇö½Ã°£ : 1½Ã°£ À̳»
- Èí¼ö : °æ±¸ : ½Å¼ÓÇÏ°Ô Èí¼öµÊ
- ´ë»ç : °£¿¡¼ glucuronide Æ÷ÇÕÀ¸·Î ¸¹Àº ¾çÀÌ ´ë»çµÊ
- ¼Ò½Ç : Æ÷ÇÕü·Î ½Å¹è¼³
|
| Biotransformation |
Chlorzoxazone¿¡ ´ëÇÑ Biotransformation Á¤º¸ Chlorzoxazone is rapidly metabolized in the liver and is excreted in the urine, primarily in a conjugated form as the glucuronide.
|
| Toxicity |
Chlorzoxazone¿¡ ´ëÇÑ Toxicity Á¤º¸ Oral, mouse: LD50 = 440 mg/kg; Oral, rat: LD50 = 763 mg/kg; Symptoms of overdose include diarrhea, dizziness, drowsiness, headache, light-headedness, nausea, and vomiting.
|
| Drug Interactions |
Chlorzoxazone¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Disulfiram Disulfiram increases chlorzoxazone levels
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸] Chlorzoxazone¿¡ ´ëÇÑ P450 table
SUBSTRATES
CYP 2E1
acetaminophen
**chlorzoxazone**
ethanol
INHIBITORS
CYP 2E1
disulfiram
INDUCERS
CYP 2E1
ethanol
isoniazid
|
| Food Interaction |
Chlorzoxazone¿¡ ´ëÇÑ Food Interaction Á¤º¸ Take without regard to meals.Avoid alcohol.
|
| Drug Target |
[Drug Target]
|
| Description |
Chlorzoxazone¿¡ ´ëÇÑ Description Á¤º¸ A centrally acting central muscle relaxant with sedative properties. It is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain. (From Martindale, The Extra Pharmacopoea, 30th ed, p1202)
|
| Drug Category |
Chlorzoxazone¿¡ ´ëÇÑ Drug_Category Á¤º¸ Muscle Relaxants, Central
|
| Smiles String Canonical |
Chlorzoxazone¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ ClC1=CC2=C(OC(=O)N2)C=C1
|
| Smiles String Isomeric |
Chlorzoxazone¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ ClC1=CC2=C(OC(=O)N2)C=C1
|
| InChI Identifier |
Chlorzoxazone¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C7H4ClNO2/c8-4-1-2-6-5(3-4)9-7(10)11-6/h1-3H,(H,9,10)/f/h9H
|
| Chemical IUPAC Name |
Chlorzoxazone¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 5-chloro-3H-1,3-benzoxazol-2-one
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2025-09-30
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
|
|
|
|